Identifying markers to predict treatment response in pancreatic cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify prognostic and predictive markers that can help determine how patients with pancreatic adenocarcinoma respond to various treatments, including surgery and chemotherapy. By analyzing a multicenter cohort derived from current clinical practice, the study seeks to evaluate the effectiveness and tolerance of these treatments. The goal is to develop tools that can stratify patients based on their estimated survival, thereby guiding therapeutic decisions and optimizing patient selection for future clinical trials.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient with histologically confirmed pancreatic adenocarcinoma.
* Disease at a resectable, borderline, locally advanced, initially metastatic, or recurrent stage after surgery
* Diagnosis between January 1, 2003, and December 31, 2030.
* First-line treatment with chemotherapy and/or radiotherapy and/or clinical trials.
* Age ≥ 18 years.
* Written informed consent

Exclusion Criteria:

* Patient under guardianship, curatorship, or judicial protection.
* Pregnant or breastfeeding women.
* Any medical, psychological, or social situation that could prevent compliance with the protocol as assessed by the investigator.
* Refusal to participate in the study

Where it's running

• CHU Jean Minjoz
  Besançon, France Recruiting
• Hôpital Beaujon
  Clichy, France Recruiting
• CHU Lille
  Lille, France Recruiting
• HRU Nancy Site Brabois
  Nancy, France Recruiting
• Hôpital Georges Pompidou
  Paris, France Recruiting
• Hôpital Saint Antoine
  Paris, France Recruiting

Study contacts

• Principal investigator: Angelique VIENOT, MD — CHRU de Besançon - Institut Régional Fédératif du Cancer (IRFC) de Franche-Comté
• Study coordinator: Angelique VIENOT, MD
• Email: regulatory.Affairs@gercor.com.fr
• Phone: 01402985 00

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Zoldonrasib plus Daraxonrasib vs Gemcitabine and Nab-Paclitaxel as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This study tests whether two investigational RAS inhibitors together can improve outcomes compared with standard chemotherapy in adults with newly diagnosed metastatic pancreatic cancer carrying the KRAS G12D mutation.

  Recruiting at 6 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 5 other locations · NCT07805954

• XYA02 in advanced solid tumors

  This trial tests XYA02 in adults with MUC1-expressing advanced or relapsed solid tumors to see if it is safe, tolerable, and can shrink tumors.

  Recruiting at 2 sites Phase 1/2 XYone Therapeutics, Inc · Sydney, New South Wales and 4 other locations · NCT07670312

• Zoldonrasib + chemotherapy vs placebo + chemotherapy as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This trial tests whether adding zoldonrasib to standard chemotherapy helps people with newly diagnosed metastatic KRAS G12D pancreatic cancer.

  Recruiting at 25 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 24 other locations · NCT07621718

• MyCap app to track time burden of pancreatic cancer treatment

  This study tests whether a mobile app can help adults with pancreatic cancer log the time they spend on cancer care.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07619391

• KRAS G12V cancer patients get TCR1188-ABC cell therapy

  This early-phase trial tests whether TCR1188-ABC cells can safely be given to adults with KRAS G12V-mutated metastatic cancers to see if it can help some types of pancreatic, biliary, colorectal, or lung cancer.

  Recruiting Phase 1 University of Pennsylvania · Philadelphia, Pennsylvania · NCT07594067

• Lorigerlimab in pancreatic cancer with BRCA/RAD51 gene mutations

  This phase 2 study tests Lorigerlimab in adults with metastatic pancreatic cancer who have BRCA1/2, PALB2, RAD51C, or RAD51D germline mutations.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT07565155

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.